2. Signaling Pathways
  3. Metabolic Enzyme/Protease
    Vitamin D Related/Nuclear Receptor
  4. LXR

LXR

Liver X receptor

LXR

Related Products

PDF 0.41 MB

LXRs (Liver X Receptor α and β) are members of the nuclear hormone receptor superfamily of ligand-activated transcription factors. LXRs are oxysterol-activated transcription factors that upregulate a suite of genes that together promote coordinated mobilization of excess cholesterol from cells and from the body. The LXRs, like other nuclear receptors, are anti-inflammatory, inhibiting signal-dependent induction of pro-inflammatory genes by nuclear factor-κB, activating protein-1, and other transcription factors.

LXRα is expressed predominately in some tissues, including the liver, kidney, macrophages, and adipose tissue. However, LXRβ is ubiquitously expressed. Activating LXRα (mainly expressed in liver) results in high triglyceride production, and growing evidence suggests that selective LXRβ agonists can reduce this side effect.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-111498
    RGX-104 hydrochloride
    		Agonist 99.88%
    RGX-104 hydrochloride is a small-molecule LXR agonist that modulates innate immunity via transcriptional activation of the ApoE gene.
    RGX-104 hydrochloride
  • HY-143259
    BE1218
    		Antagonist 99.86%
    BE1218 is a liver X receptor (LXR) inverse agonist with IC50 values of 9 nM and 7 nM against LXRα and LXRβ, respectively.
    BE1218
  • HY-123148
    IMB-808
    		Agonist 99.85%
    IMB-808 is a potent LXRα/β dual agonist with EC50 values of 0.53 μM and 0.15 μM (0.15 μM, using GAL4-pGL4-luc reporter plasmid) for LXRβ and LXRα, respectively. IMB-808 promotes expression of genes related to reverse cholesterol transport (ABCA1 and ABCG1). IMB-808 can be used as a promising agent for the prospective treatment of atherosclerosis research.
    IMB-808
  • HY-154928
    GW6340
    		Agonist 99.64%
    GW6340 is an intestinal-specific LXR agonist. GW6340 promotes macrophage reverse cholesterol transport (mRCT).
    GW6340
  • HY-125772
    Acetyl podocarpic acid anhydride
    		Agonist ≥99.0%
    Acetyl podocarpic acid anhydride is a potent, semisynthetic liver X receptor(LXR) agonist derived from extracts of the mayapple. Acetyl podocarpic acid anhydride has the potential to be useful for the prevention and research of atherosclerosis, especially in the context of low HDL levels.
    Acetyl podocarpic acid anhydride
  • HY-109073
    Rovazolac
    		Modulator 99.68%
    Rovazolac is a liver x receptor (LXR) modulator extracted from patent WO2013130892A1.
    Rovazolac
  • HY-N3216
    Nagilactone B
    		Agonist ≥98.0%
    Nagilactone B is a liver X receptor (LXR) agonist.
    Nagilactone B
  • HY-D1734
    FITC-GW3965
    		Agonist ≥98.0%
    FITC-GW3965 is a fluorescence-labelled liver X receptor β (LXRβ) agonist GW3965 (HY-10627). FITC-GW3965 is a tracer, that can be designed by replacing the trifluoromethyl of GW3965 with an amide to link the FITC. FITC-GW3965 can be used to study the function of LXRβ.
    FITC-GW3965
  • HY-N2078
    Yamogenin
    		Antagonist 98.80%
    Yamogenin (Neodiosgenin) is a diastereomer of diosgenin. Yamogenin (Neodiosgenin) antagonizes the activation of the liver X receptor (LXR) in luciferase ligand assay. Yamogenin (Neodiosgenin) inhibits triacylglyceride (TG) accumulation through the suppression of gene expression of fatty acid synthesis in HepG2 hepatocytes.
    Yamogenin
  • HY-10627
    GW3965
    		Agonist
    GW3965 is a potent, selective liver X receptor (LXR) agonist with EC50s of 190 nM and 30 nM for hLXRα and hLXRβ, respectively.
    GW3965
  • HY-100469
    LXRβ agonist-2
    		Agonist
    LXRβ agonist-2 is a highly potent and β-selective liver X receptor (LXRβ) agonist with EC50 of 7 nM, displays 28.5-fold selectivity over LXRα (EC50=200 nM) and used in the treatment of atherosclerosis.
    LXRβ agonist-2
  • HY-152262
    LXRβ agonist-4
    		Agonist
    LXRβ agonist-4 is a potent, orally active Liver X receptors (LXRs) agonist with an IC50 value of 0.0078 μM for LXRβ. LXRβ agonist-4 inhibits RANKL-induced osteoclast differentiation and bone resorption. LXRβ agonist-4 can be used in research of osteoporosis.
    LXRβ agonist-4
  • HY-N2509
    Iristectorigenin B
    		Agonist 99.49%
    Iristectorigenin B (Iristectrigenin B) is a liver X receptor (LXR) modulator. Iristectrigenin B stimulates the transcriptional activity of both LXR-α and LXR-β.
    Iristectorigenin B
  • HY-146288
    LXR agonist 2
    		Agonist
    LXR agonist 2 (compound 18rr) is a potent LXR (liver X receptor) agonist. LXR agonist 2 can stabilize NCOA1 (co-activator), leading to LXR agonism.
    LXR agonist 2
  • HY-144549
    LXR agonist 1
    		Agonist
    LXR (Liver X receptor) agonist 1 is potent LXR agonist with AC50s of 1.5 nM and 12 nM for LXR-α and LXR-β, respectively. LXR agonist 1 has the potential for the research of atherosclerosis.
    LXR agonist 1
  • HY-116969
    22(R)-Hydroxycholesterol
    		Agonist
    22(R)-Hydroxycholesterol (Narthesterol) is an endogenous LXR agonist. 22(R)-Hydroxycholesterol (Narthesterol) can be used for tangier disease research.
    22(R)-Hydroxycholesterol
  • HY-N12619
    12R,13S-Dihydroxyfumitremorgin C
    		Agonist
    12R,13S-Dihydroxyfumitremorgin C (compound 1) is a LXRα agonist.
    12R,13S-Dihydroxyfumitremorgin C
  • HY-146275
    LXRβ agonist-3
    		Agonist
    LXRβ agonist-3 (compound 4-13) is a potent and selective LXRβ (liver X receptor β) agonist, with an EC50 of 0.095 μM. LXRβ agonist-3 efficiently inhibits U87EGFRvIII cell, with an IC50 of 3.75 μM. LXRβ agonist-3 shows antitumor activity, and can inhibit glioblastoma.
    LXRβ agonist-3
  • HY-W040150
    (24S,25)-Epoxycholesterol
    		Agonist
    24S,25-Epoxycholesterol is an agonist for Liver X Receptor (LXR). 24S,25-Epoxycholesterol exhibits properties in regulating the cholesterol efflux, inhibiting tumor growth against gastric cancer and glioblastoma and inducing apoptosis in BMMC cells.
    (24S,25)-Epoxycholesterol
Cat. No. Product Name / Synonyms Application Reactivity